October 26, 2021, Vol 326, No. 16, Pages 1565-1642
Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021
Emily Jane Woo, MD, MPH; Adamma Mba-Jonas, MD, MPH; Rositsa B. Dimova, PhD; et al.
JAMA. 2021;326(16):1606-1613. doi:10.1001/jama.2021.16496
Based on the Vaccine Adverse Event Reporting System, this article reports on the prevalence of presumptive Guillain-Barré syndrome among recipients of the Ad26.COV2.S (Janssen/Johnson & Johnson) COVID-19 vaccine.